As Actavis business improves, Aurobindo sees early turnaround

G Naga Sridhar Hyderabad | Updated on June 17, 2014 Published on June 17, 2014

Actavis’ European operations acquired for €30 million

Aurobindo Pharma Ltd, which acquired certain loss-making operations of Irish drug-maker Actavis Plc early this year, says the acquired business is improving in line with its expectations.

In January, the Hyderabad-based drug-maker said it had acquired commercial operations of Actavis in seven Western European countries for €30 million (around ₹240 crore today).

“Having seen the operations for the last two months, we are quite confident (about its turnaround). Things are in line with what the due diligence understanding was,” CEO Arvind Vasudeva said in the earnings conference call recently.

He added the acquired business will be EBITDA-neutral in two years.

Towards this, Aurobindo will bring some products of Actavis into the domestic market to take advantage of its lower active pharmaceutical ingredients (APIs) and manufacturing costs over the next 18 to 24 months.

In addition, operational optimisation would be taken up where ever possible, Vasudeva added.

The company hopes to grow its revenue at 10 per cent in the European market by putting together Actavis in its portfolio.

It would strengthen its European operations, adding capabilities in France, Italy, Spain, Portugal, Germany, the Netherlands and Belgium, and brands such as Arrow Generiques.

In 2013-14, Aurobindo’s revenue from Europe increased 43.6 per cent to ₹672 crore.

For the full-year, its profit increased to ₹1,173 crore from ₹294 crore in the previous year. Total revenue rose to ₹8,100 crore from ₹5,855 crore in FY13.

On Tuesday, Aurobindo’s scrip closed at ₹707.65, down 0.04 per cent, on the BSE.

Published on June 17, 2014

A letter from the Editor

Dear Readers,

The coronavirus crisis has changed the world completely in the last few months. All of us have been locked into our homes, economic activity has come to a near standstill. Everyone has been impacted.

Including your favourite business and financial newspaper. Our printing and distribution chains have been severely disrupted across the country, leaving readers without access to newspapers. Newspaper delivery agents have also been unable to service their customers because of multiple restrictions.

In these difficult times, we, at BusinessLine have been working continuously every day so that you are informed about all the developments – whether on the pandemic, on policy responses, or the impact on the world of business and finance. Our team has been working round the clock to keep track of developments so that you – the reader – gets accurate information and actionable insights so that you can protect your jobs, businesses, finances and investments.

We are trying our best to ensure the newspaper reaches your hands every day. We have also ensured that even if your paper is not delivered, you can access BusinessLine in the e-paper format – just as it appears in print. Our website and apps too, are updated every minute, so that you can access the information you want anywhere, anytime.

But all this comes at a heavy cost. As you are aware, the lockdowns have wiped out almost all our entire revenue stream. Sustaining our quality journalism has become extremely challenging. That we have managed so far is thanks to your support. I thank all our subscribers – print and digital – for your support.

I appeal to all or readers to help us navigate these challenging times and help sustain one of the truly independent and credible voices in the world of Indian journalism. Doing so is easy. You can help us enormously simply by subscribing to our digital or e-paper editions. We offer several affordable subscription plans for our website, which includes Portfolio, our investment advisory section that offers rich investment advice from our highly qualified, in-house Research Bureau, the only such team in the Indian newspaper industry.

A little help from you can make a huge difference to the cause of quality journalism!

Support Quality Journalism
This article is closed for comments.
Please Email the Editor
You have read 1 out of 3 free articles for this week. For full access, please subscribe and get unlimited access to all sections.